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Type 2 diabetes (T2D) is a prevalent risk factor for tuberculosis (TB), but most studies on TB-T2D have focused
on TB patients, been limited to one community, and shown a variable impact of T2D on TB risk or treatment
outcomes. We conducted a cross-sectional assessment of sociodemographic and metabolic factors in adult TB
contacts with T2D (versus no T2D), from the Texas-Mexico border to study Hispanics, and in Cape Town to study
South African Coloured ethnicities. The prevalence of T2D was 30.2% in Texas-Mexico and 17.4% in South
Africa, with new diagnosis in 34.4% and 43.9%, respectively. Contacts with T2D diﬀered between ethnicities,
with higher smoking, hormonal contraceptive use and cholesterol levels in South Africa, and higher obesity in
Texas-Mexico (p < 0.05). PCA analysis revealed striking diﬀerences between ethnicities in the relationships
between factors deﬁning T2D and dyslipidemias. Our ﬁndings suggest that screening for new T2D in adult TB
contacts is eﬀective to identify new T2D patients at risk for TB. Furthermore, studies aimed at predicting individual TB risk in T2D patients, should take into account the heterogeneity in dyslipidemias that are likely to
modify the estimates of TB risk or adverse treatment outcomes that are generally attributed to T2D alone.

List of abbreviations: T2D, Type 2 diabetes; TB, Tuberculosis; WHO, World Health Organization; BMI, body-mass index; LDL-c, Low-density lipoprotein cholesterol;
HDL-c, High-density lipoprotein cholesterol; HIV, Human immunodeﬁciency virus; HOMA-IR, homeostasis model assessment for insulin resistance; LTBI, Latent TB
infection; PCA, Principal Component Analysis; ANCOVA, Analysis of covariance
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1. Introduction

HbA1c 5.7–6.49% [17]. Macro- and micro-vascular pathologies were
self-reported. The frequency of alcohol consumption and the average
number of alcoholic drinks consumed in a typical day were established
using validated questions described previously [18]. Alcohol excess was
deﬁned as drinking ≥7 drinks/episode at least weekly or binge
drinking (≥10 drinks/episode at least twice a month), and alcohol
abuse was deﬁned as consumption of more than 7 drinks per day on a
daily basis. Drug use was based on self-reported use of injectable or
non-injectable illicit drugs at least twice per week. Latent TB infection
(LTBI) was based on QuantiFERON-Gold In-Tube (Qiagen). Plasma LDL
cholesterol (LDL-c) was measured in South Africa, and calculated for
Texas [Total cholesterol - HDL-c - (Triglycerides *0.20)] [19]. Insulin
resistance was based on the homeostasis model assessment (HOMA-IR)
[fasting plasma glucose (mM)*fasting serum insulin (mU/L)/22.5] on
participants who did not use insulin [20].
Data were entered into RedCap (Vanderbilt University) and exported into SAS (v9.4 Cary, NC) or SPSS (v23.0 Armonk, NY) for analysis. Chi-square or Fisher's exact tests were used to compare categorical
variables and two-sample test proportions to identify diﬀerences between study sites. Mixed-model designs for analysis of covariance
(ANCOVA) were performed and the F statistic transformed to Cohen-d.
A Latent Factor analysis using Principal Components approach (PCA)
was done and Varimax axes rotation was used for eigen vector interpretation. P values were considered signiﬁcant if ≤ 0.05, and marginally signiﬁcant if < 0.1.

The growing pandemic of type 2 diabetes mellitus (T2D) is a challenge to tuberculosis (TB) control. Individuals with T2D have a 3-fold
increased risk of TB, particularly if they have poor glucose control or
additional T2D complications [1–3]. However, the increased TB risk in
patients with T2D varies widely between studies, regions and populations, with risk estimates ranging from 0.99 to 7.83. Likewise, at the
population level, the contribution of T2D to TB is generally between 10
and 20%, with substantial variation depending on the local epidemiology [1,4].
Once a patient with T2D develops TB, they appear to be more likely
to have delays in the conversion of sputum smears from positive to
negative during TB treatment, to fail treatment, or to relapse [5–7].
However, not all studies report these associations between adverse
treatment outcomes and T2D, and if so, there are variations in their
magnitude. This heterogeneity illustrates the complexity of studying
T2D as a risk factor for TB and may be explained by variability in study
populations with respect to T2D (e.g., glucose control, medications, comorbidities), sociodemographics and access to healthcare, or variations
in study designs [8]. Few interactions between T2D and other host
characteristics have been described, as suggested for T2D plus smoking
or micro and macro-vascular diseases [9–12]. While more studies of this
nature are needed among TB patients, there are even fewer studies in
TB contacts with T2D. This is a particularly important population for TB
control given that TB contacts have one of the highest risks for TB
progression (5% in the ﬁrst year of exposure to a pulmonary TB patient), and those with T2D will magnify this risk by 3-fold [3,13].
The goal of the present study was to compare sociodemographic and
metabolic risk factors for TB among TB contacts with T2D from two
distant communities with diﬀering ethnicities and cultures. We enrolled
South African Coloureds in the Western Cape of South Africa (TB 625/
100,000/year; HIV < 6%; T2D range 8–28%), and Hispanics in south
Texas (T2D 19%; HIV 0.14/100,000; TB 10/100,000/year) and
northern Mexico (T2D 15%; TB 32/100,000/year) [1,14–16]. Our study
revealed two major ﬁndings: A high frequency of new T2D among the
TB contacts from both regions, and striking diﬀerences between ethnicities in metabolic and sociodemographic characteristics that are
likely to modify the risk of TB conferred by T2D.

3. Results
3.1. Characteristics of all TB contacts
We enrolled 95 contacts (after screening 247 for T2D) in South
Africa, and 106 in Texas-Mexico (46 in Mexico and 60 in Texas; all
those screened were enrolled). The contacts from both sites were predominantly females, but diﬀered in several aspects: In Texas-Mexico
nearly all (98%) were Hispanic whites and in South Africa all were
South African Coloureds, a mixed ancestry population with Khoisan,
Bantu, European and Asian roots. The Texas-Mexico contacts were
younger, more educated and obese (Fig. 1A; p < 0.001), while those in
South Africa were more likely to smoke and there was a higher proportion of females reporting contraceptive use (Table 1; p < 0.003).
Their medical history diﬀered between study sites in various ways
(Table S1). Those in Texas-Mexico were more likely to have a family
history of T2D (p = 0.005), take anti-inﬂammatory medications
(p = 0.002) or vitamin supplements (p = 0.001) and were less likely to
have previous TB or current LTBI (p < 0.001).

2. Methods
Participants were enrolled at clinics in south Texas (Hidalgo and
Cameron County Health Departments), northern Mexico (Centro
Regional de Tuberculosis in Reynosa; ‘Texas-Mexico’ in this study) and
South Africa (public healthcare clinics around the Tygerberg Academic
Hospital in Cape Town; ‘South Africa’ in this study). Close contacts were
deﬁned as sharing at least 5 h per week in a house or closed space with
a conﬁrmed pulmonary TB source. Active TB was ruled out based on
lack of signs and symptoms compatible with TB, and by normal chest xray (routine in Texas and South Africa, and upon physician request in
Mexico). At both study sites, we enriched for T2D by initially enrolling
contacts 30–65 years old and eventually elevating the lower age to 35
years. In South Africa, all eligible participants were screened for T2D by
HbA1c and FBG to determine accurate prevalence data. From those, all
participants with an HbA1c ≥ 6.5% were fully enrolled into the study
and blood samples were collected for the downstream analysis, whereas
only randomly selected participants with HbA1c ≤ 6.5% were enrolled
on the basis of one normoglycemic participant per participant with
hyperglycemia. Exclusion criteria included a body-mass index
(BMI) < 18.5, HIV infection, type 1 diabetes, cancer and recent infections. The study was approved by the institutional review boards of
the participating institutions and participants signed a free informed
consent.
Diabetes classiﬁcation was based on hyperglycemia (fasting plasma
glucose ≥126 mg/dL), HbA1c ≥ 6.5% or self-report, and pre-T2D as

3.2. Prevalence of pre-T2D and T2D
In Texas-Mexico we identiﬁed 32 contacts with T2D (30.2%) and 26
with pre-T2D (24.5%; 54.7% with both). In South Africa, we screened
for elevated HbA1c in 247 TB contacts and identiﬁed 43 with T2D
(17.4%) and 56 with pre-T2D (22.7%; 40.1% with both). Thus, the
prevalence of T2D and pre-T2D was high in both communities, and
signiﬁcantly higher in Texas-Mexico (p = 0.007). Among those with
T2D, 34.4% were newly diagnosed in Texas-Mexico and 43.9% in South
Africa. In South Africa, we invited all of the pre-screened contacts with
T2D and a similar number of no T2D controls (without taking into
account pre-T2D status) for full enrollment [total n = 95; 41 (43.2%)
with T2D and 21 (22.1%) with pre-T2D].
3.3. Sociodemographics and medical history by T2D status and study site
Analysis was done by T2D status (2 categories) and also including
pre-T2D (3 categories), but the latter results are only described when
there were detectable diﬀerences in the pre-T2D group. The contacts
with T2D (versus no T2D) were older at both study sites, and in South
11
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Fig. 1. Body-mass index and waist-hip ratio in contacts by T2D status and enrollment site. A. Body-mass index was classiﬁed as normal, overweight or obese (see
methods). B. Waist-hip ratio estimates were categorized into two groups: excellent plus good or average, or at risk, with cut-oﬀs diﬀering by sex (see methods). The
proportion of the contacts in each category is shown by T2D status.

3.4. Glucose metabolism-related characteristics by T2D status and study site

Africa they were also more likely to be obese and female (Table 1).
Contacts with T2D (versus no T2D) from both study sites were more
likely to have a family history of T2D, and a higher frequency of macro
or micro-vascular complications. Between study sites, the T2D contacts
from Texas-Mexico (versus South Africa) had a higher level of education, were more obese and had higher waist-hip ratios, but reported less
smoking (p < 0.001) or hormonal contraceptive use (Table 1;
p = 0.003). The T2D patients from Texas-Mexico (versus South Africa)
were more likely to take anti-inﬂammatory medications (p = 0.006)
and vitamin supplements (p = 0.017), but they were less likely to have
a previous history of TB (p = 0.013) or current LTBI (p = 0.008; Table
S1).

There were three diﬀerences between the T2D contacts from both
study sites with respect to glucose metabolism. First, there was a trend
for a higher proportion of elevated HbA1c in the presence of otherwise
normal fasting plasma glucose in South Africa (34.1%) versus TexasMexico (18.2%); Fig. 2; (p = 0.128). The second diﬀerence was related
to insulin resistance. As expected, insulin levels and insulin resistance
(HOMA-IR) were higher among the T2D contacts (Table 2), but insulin
resistance was also higher in the no T2D contacts from Texas-Mexico
versus South Africa (p = 0.017). We hypothesize this diﬀerence was
related to the higher BMI and triglycerides in Texas-Mexico (Tables 1
and 2; Figs. 1 and 4), given that insulin resistance is associated with
12
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Table 1
Sociodemographic characteristics of TB contacts, by study site and T2D status.a
Texas-Mexico
All

Age in yrs (median, IQR)
Age groups
30 to 35
36 to 59
60 to 65
Sex
Male
Female
Highest Education
Elementary
Middle
High school
College
Smoking
Never smoked
Past smoker
Current smoker
Alcohol excess
Drugs
Contraceptive hormonesc
Waist-Hip ratiod
Normal
At risk
BMI (median, IQR)
BMI categories
Normal (18.5–24.9)
Overweight (25–29.9)
Obese (30+)
a
b
c
d

Texas-Mexico vs South Africab

South Africa
Type 2 diabetes
No T2D

T2D

n = 106

74 (69.8%)

32 (30.2%)

44(13)

42.5(13)

49(16)

17(16%)
77(72.6%)
12(11.3%)

15(20.3%)
53(71.6%)
6(8.1%)

2(6.3%)
24(75.0%)
6(18.8%)

35(33%)
71(67%)

27(36.5%)
47(63.5%)

8(25.0%)
24(75.0%)

12(11.8%)
26(25.5%)
24(23.5%)
40(39.2%)

8(10.8%)
18(24.3%)
19(25.7%)
29(39.2%)

4(14.3%)
8(28.6%)
5(17.9%)
11(39.3%)

68(64.2%)
15(14.2%)
23(21.7%)
7(6.6%)
5(4.7%)
4(5.6%)

46(62.2%)
10(13.5%)
18(24.3%)
5(6.8%)
4(5.4%)
4(8.5%)

22(68.8%)
5(15.6%)
5(15.6%)
2(6.3%)
1(3.1%)
0(0%)

26(26.3%)
73(73.7%)
29.4(7.9)

21(30.4%)
48(69.6%)
29.1(8.2%)

5(16.7%)
25(83.3%)
30.1(7.2%)

20(19.0%)
37(35.2%)
48(45.7%)

17(23.3%)
25(34.2%)
31(42.5%)

3(9.4%)
12(37.5%)
17(53.1%)

All

Type 2 diabetes

P

0.011
0.082

No T2D

T2D

P

n = 95

54 (56.8%)

41 (43.2%)

49(14)

45.5(13)

53(13)

10(10.5%)
78(82.1%)
7(7.4%)

8(14.8%)
44(81.5%)
2(3.7%)

2(4.9%)
34(82.9%)
5(12.2%)

28(29.5%)
67(70.5%)

21(38.8%)
33(61.2%)

7(17.1%)
34(82.9%)

10(10.5%)
28(29.5%)
52(54.7%)
5(5.3%)

6(11.1%)
14(25.9%)
31(57.4%)
3(5.6%)

4(9.8%)
14(34.1%)
21(51.1%)
2(4.9%)

17(20.2%)
6(7.1%)
61(72.6%)
4(4.2%)
10(10.6%)
13(19.4%)

11(23.4%)
1(2.1%)
35(74.5%)
2(3.7%)
8(14.8%)
9(27.3%)

6(16.2%)
5(13.5%)
26(70.3%)
2(4.9%)
2(4.9%)
4(11.8%)

47 (49.5%)
48 (50.5%)
26.2(10.5)

30 (54.5%)
24 (44.4%)
24.8(8.6%)

17(42.5%)
24 (58.5%)
28.5(10.8%)

42(44.7%)
21(22.3%)
31(33.0%)

29(54.7%)
11(20.7%)
13(24.5%)

13(31.7%)
10(24.4%)
18(43.9%)

0.021

0.830

T2D

P

P

P

0.253
0.110
< 0.001
0.563

0.248
0.197
0.310
0.791

0.795
0.407
0.434
0.407

0.770
0.526
< 0.001
< 0.001

0.957
0.836
< 0.001
< 0.001

0.554
0.616
0.004
< 0.001

< 0.001
< 0.001
< 0.001
0.476
0.118
0.003
0.001

< 0.001
0.024
< 0.001
0.447
0.071
0.005
0.006

< 0.001
0.800
< 0.001
0.795
0.701
0.044
0.018

0.002

< 0.001

0.421

< 0.001
0.044
0.066

< 0.001
0.095
0.035

0.022
0.226
0.435

0.859

0.606

0.500
0.237

No T2D

< 0.001
0.107

0.248

0.645
0.522
0.184
0.153

All

0.114

0.778
0.134
0.109
0.174

0.008
0.064

Data expressed as n(column %) unless speciﬁed.
p-value using two sample proportion using column percentage.
Females only.
Waist:hip ratio classiﬁed as normal (< 0.90 in males; < 0.86 in females) or at risk if higher; Bold p values are signiﬁcant or borderline signiﬁcant.

dispersion (an indication of error due to the contribution of other
variables to HOMA-IR), we tested several models. Smoking, drugs, alcohol and contraceptives were not associated with HOMA-IR. The
model with the best ﬁt for the HOMA-IR variable required adjustment
for study site, age and sex, and the interaction between BMI*triglycerides (Cohen d = 0.95, p < 0.001, Fig. 3A). We further visualized these adjusted relationships with 3D surface plots (Fig. 3B–C).

obesity and can be driven by free fatty acids, which are triglyceride
metabolites [21]. Thus, we evaluated the relationships between BMI or
triglycerides on HOMA-IR. As expected, in each country we found that
HOMA-IR values were positively correlated with triglycerides
(rho = 0.34 in Texas-Mexico; rho = 0.37 in South Africa; p < 0.001)
and BMI (rho = 0.38 in Texas-Mexico; rho = 0.53 in South Africa;
p < 0.001; Fig. S1). Because these bivariate analyses showed

Fig. 2. Criteria for diagnosis of T2D by study site.
T2D diagnosis was based on the current WHO
guidelines (see methods). The proportion of contacts
fulﬁlling each criterium for T2D classiﬁcation is indicated by study site. SR = self-reported only; ↑
Glu
=
hyperglycemia
only;
↑
HbA1c
=
HbA1c
≥
6.5%
only;
↑
Glu + HbA1c = Both high glucose and HbA1c.

13
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Table 2
Lipids, insulin and insulin resistance by T2D status and study site.
Texas-Mexico
ALL

Type 2 diabetes
No T2D

T2D

ALL

Type 2 diabetes

P

Lipid proﬁles (n, column %)a
Triglycerides
0.003
Normal
66(62.3%)
53(71.6%)
13(40.6%)
70(74.5%)
High
40(37.7%)
21(28.4%)
19(59.4%)
24(25.5%)
Total cholesterol
0.063
Normal
95(89.6%)
69(93.2%)
26(81.3%)
62(66.0%)
High
11(10.4%)
5(6.8%)
6(18.8%)
32(34.0%)
LDL
0.404
Normal
70(66%)
47(63.5%)
23(71,9%)
41(45.6%)
High
36(34%)
27(36.5%)
9(28.1%)
49(54.4%)
Male HDL (cut-oﬀ = 40)
0.685
Normal
11(31.4%)
8(29.6%)
3(37.5%)
21(77.8%)
Low
24(68.6%)
19(70.4%)
5(62.5%)
6(22.2%)
Female HDL (cut-oﬀ = 50)
0.075
Normal
28(39.4%)
22(46.8%)
6(25%)
35(52.2%)
Low
43(60.6%)
25(53.2%)
18(75%)
32(47.8%)
Glucose, HbA1c, insulin and HOMA-IR as estimate of insulin resistance (median, IQR)
Glucose (mg/dL)
104.5(35)
96.5(20)
167.5(114.5)
< 0.001
97.3(59.5)
HbA1c (%)
5.7(1.5)
5.5(0.4)
8.0(2.9)
< 0.001
6.0(2)
c
Insulin (mU/L)
11.6 (9.2)
11.1 (8.4)
13.6 (9.4)
0.133
11.7(11.9)
c
HOMA-IR
3.3 (3.2)
2.7 (2.0)
6.7 (4.4)
< 0.001
2.8 (4.7)
a
b
c

Texas-Mexico vs South Africab

South Africa

No T2D

T2D

45(84.9%)
8(15.1%)

25(61.0%)
16(39.0%)

39(73.6%)
14(25.9%)

23(56.1%)
18(45%)

29(55.8%)
23(43.4%)

12(31.6%)
26(70.3%)

18(90%)
2(10%)

3(42.9%)
4(57.1%)

19(57.6%)
14(41.2%)

16(47.1%)
18(54.5%)

86.5(19.8)
5.5(0.7)
9.8(8.9)
1.9(2.4)

163.1(132.4)
7.9(3.5)
15.6(20.5)
5.9(5.6)

All

No T2D

T2D

P

P

P

P

0.008

0.065

0.077

0.083

0.076

< 0.001

0.003

0.019

0.023

0.004

0.430

< 0.001

0.010

< 0.001

< 0.001

0.641

0.389

0.131

0.180

0.071

< 0.001
< 0.001
< 0.001
< 0.001

0.072
0.090
0.960
0.832

< 0.001
0.683
0.077
0.017

0.306
0.605
0.194
0.376

Values in mg/dL.
p-value using two sample proportion using column percentage.
Data from non-insulin users only; Bold values are signiﬁcant or borderline signiﬁcant.

Fig. 3. Relationship between adjusted HOMA-IR, BMI and triglycerides. (A) Scatter plot of correlation between adjusted HOMA-IR and triglycerides (mg/dL) by study
site. The eﬀect size was d = 0.95 for triglycerides*BMI (p < 0.001). Analysis was made with ANCOVA with adjustment for site, age, BMI, sex, triglycerides and
sex*site, sex*age and BMI*triglycerides. (B and C) Surface plots of the relationships between adjusted HOMA-IR, BMI and triglycerides in Texas-Mexico and South
Africa. In South Africa there were few individuals with triglycerides below 200 mg/dl, computing unstable coeﬃcients and increasing noise in these points.

We expanded on the observed diﬀerences by analyzing the inﬂuence
of study sites, T2D status, sex and age, on the various lipid levels. We
found that triglycerides were higher in Texas-Mexico and in T2D patients (Cohen-d = 0.43–0.44; Fig. 4A). Total cholesterol was higher in
South Africans (Cohen-d = 0.67), but was not aﬀected by T2D status
(Fig. 4B). HDL-c was lower in pre-T2D and T2D in Texas-Mexico
(Cohen-d = 0.43 and 0.5; Fig. 4C). Finally, LDLs had an interaction
eﬀect between study site and T2D status (Cohen-d = 0.38) (Fig. 4D). In
summary, lipid levels were mainly inﬂuenced by study site and T2D
status.

At both study sites, the simultaneous increase in BMI and triglycerides
was correlated with increased adjusted HOMA-IR, but in South Africa
some individuals also had high adjusted HOMA-IR despite normal triglycerides. This ANCOVA model revealed a third diﬀerence in glucose
metabolism between study sites: a diﬀerential contribution of sex to
adjusted HOMA-IR by study site, with higher insulin resistance in
women from South Africa (mean 5.5, 95% CI 4.7, 6.2) versus TexasMexico (mean 3.9, 95% CI 3.2, 4.7; Fig. S2).
3.5. Lipid metabolism-related characteristics by study site and T2D status

3.6. Relationship between metabolic factors underlying T2D at both study
sites

The contacts from both study sites diﬀered in their lipid proﬁles
(Table 2). The most prevalent dyslipidemias were high triglycerides and
low HDL (among females) in Texas-Mexico and high LDL-c cholesterols
in South Africa (p < 0.05). The contacts with T2D (versus no T2D)
from both study sites were more likely to have high triglycerides and
total cholesterol (Table 2). Sex also had an eﬀect on altered HDL-c, with
diﬀerences between countries. Smoking, drugs, alcohol and contraceptives were not associated with lipids in either country.

Our analysis of two study populations indicated variable relationships between metabolic factors that deﬁne T2D (hyperglycemia,
HbA1c, HOMA-IR), obesity (BMI, waist-hip ratio) and dyslipidemias
(triglycerides, total cholesterol, LDL-c and HDL-c). To further understand these relationships, we conducted a Latent Factor analysis of
14
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Fig. 4. Dyslipidemia by study site and T2D status. Analysis of covariance contrasts lipid serum concentration (outcomes A-D) by T2D status (no T2D, pre-T2D and
T2D) and between sites, after controlling for age and sex. Fisher contrast was used for T2D status as indicator variable (ﬁxed factor), study site (random factor) and
the model was adjusted for sex and age. A) Triglycerides were higher in Texas-Mexico (Cohen-d = 0.43, p = 0.002), and in T2D patients (Cohen-d = 0.44,
p = 0.003), but not pre-T2D. B) Total cholesterol was higher in South Africa (Cohen-d = 0.67, p = 0.0001), but was not aﬀected by T2D status. C) HDL-c was lower
in pre-T2D (0.011) and T2D (Cohen-d = 0.43, p = 0.006), in Texas-Mexico (Cohen-d = 0.5, p = 0.001). D) LDLs had an interaction eﬀect between study site and
T2D status (Cohen-d = 0.38, p = 0.045). Vertical lines indicate 95% conﬁdence intervals; Common letters indicate homogenous groups within T2D groups and *
indicates diﬀerences by study site.

Fig. 5. Relationship between variables related to BMI and glucose and lipid metabolism in South Africa and Texas-Mexico. Analysis and visualization of the
correlations between variables deﬁning T2D (HbA1c, HOMA-IR), obesity (waist-hip ratio, BMI) and lipid metabolism (LDL-c, HDL-c, triglycerides) by PCA analysis.
The Kaiser-Meier-Olkin sampling adequacy was 0.627 for South Africa and 0.5 for Texas-Mexico, and Barttlet's test of sphericity was < 0.001 for both sites. A) In
South Africa the ﬁrst two components (PC 1 with correlated variables HbA1c, HOMA-IR, triglycerides, LDL, and waist-hip ratio, and PC2 with inversely correlated
variables BMI and HDL) explained 53% of the variability. B and C) The data from Texas-Mexico required four components (PC1 with triglycerides and HDL-c; PC2
with HOMA-IR and HbA1c; PC3 with waist-hip ratio and BMI; PC4 with LDL-c) to explain 79% of the total variability. Figure C shows the rotated component matrix
of B to illustrate the separation of LDL from the other variables. SAfr, South Africa; TxMx, Texas-Mexico.

4. Discussion

these variables using PCA for each study site. We found that South
Africa had two components that explained 53% of variability on the
seven variables, while Texas-Mexico required four components to describe the relationships between these same variables, and explained
79% of total variability (Fig. 5; Table S2).

To our knowledge, this is the ﬁrst study to provide an in-depth
description of the sociodemographic and metabolic characteristics of
adult contacts of TB patients from two distant communities with different ethnicities: The Texas-Mexico border region in North America
and the Western Cape of South Africa. We report two major ﬁndings.
First, both communities revealed high prevalence rates (at least 40%) of
15
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of TB associated with statin therapy (which lowers cholesterol) [32,33].
The impact of triglycerides on TB risk is unclear, even though Mtb has
been shown to modulate lipolysis and use fatty acids from the host cell
[34].
The PCA analysis conﬁrmed that our study sites diﬀer in the relationships between metabolic elements associated with T2D, where
some may increase TB risk (total or LDL cholesterol) and others may be
protective (e.g. BMI). In South Africa, HOMA-IR and HbA1c were correlated with triglycerides, LDL-c and waist-hip ratio. These are known
cardiovascular disease risk factors, particularly for T2D patients [35].
In contrast, in Hispanics, HOMA-IR and HbA1c failed to correlate with
these cardiovascular risk factors (Fig. 5). These diﬀerences in the underlying metabolic status may contribute to the poorly understood
variability in TB risk estimates among T2D patients worldwide [4,11].
For example, recent studies suggest that the higher death rate in TBT2D patients is due to T2D complications, including a study in Tanzania
[9,11,36,37]. Thus, one would predict that TB-T2D patients with cardiovascular diseases are more likely to die. Anecdotally, our studies in
Texas-Mexico have failed to detect higher risk of death among TB-T2D
patients versus TB alone, even after controlling for potential confounders [38].
Sociodemographic factors that increase TB risk were also distributed
diﬀerently between both study site. Notably, the T2D patients from
South Africa had higher smoking rates. Smoking is a risk factor for
progression from latent to active TB [39], and the co-existence of T2D
plus smoking has been associated with higher risk of TB or higher
prevalence of MDR-TB or death during TB treatment [9,12,40]. A
greater proportion of female participants at the South African site reported hormonal contraceptive use. We have shown that medroxyprogesterone acetate decreases M. bovis BCG-induced cytokine production in MPA users [41], and increases the M. tuberculosis burden in
mice [42].
We recognize study limitations such as a relatively small sample
size. Both study sites had a higher proportion of females, which reﬂect
their higher willingness to participate in research studies. Thus, extrapolation of our ﬁndings to the entire community must be done with
caution.

combined pre-T2D and T2D, and at least 30% of undiagnosed T2D.
These statistics provide support for evaluating the expansion of current
TB contact screening protocols to include T2D screening. Second, our
analysis revealed diﬀerences in epidemiologic factors (smoking, education and contraceptive use) and metabolic status (glycated hemoglobin, insulin resistance, dyslipidemia and obesity) between the
T2D patients from both ethnicities. Sex had a diﬀerential inﬂuence by
study site on the metabolic status. Deﬁnition of these complex relationships is a critical step forward in understanding how these factors
aﬀect the magnitude of the contribution of T2D to the risk and adverse
outcomes for TB in diﬀerent ethnic groups.
Previous studies have shown that the screening of TB patients for
T2D is eﬀective to detect new T2D, particularly in developing countries
where T2D awareness is lower [1,4,22]. We now ﬁnd that screening for
T2D among adult TB contacts, a population at high risk for TB, can be
very eﬀective in identifying individuals with T2D. In Texas-Mexico a
lack of T2D awareness was observed on both sides of the border [6/15
(40%) in Texas; 5/17 (29.4%) in Mexico]. Thus, T2D screening among
contacts is not only beneﬁcial in developing countries as suggested in a
recent report from India, but also in populations with severe health
disparities from developed countries [23]. The participating counties in
south Texas are among the poorest counties in the US, and the enrolled
TB contacts were in the lowest 20% percentile of this community (data
not shown) [24]. In South Africa, the proportion of new T2D among all
T2D patients was even higher at 43.9%, a ﬁgure consistent with the
estimated lack of T2D awareness in nearly two thirds of the adults with
T2D in sub-Saharan Africa [25]. Possible explanations for the high
proportion of new T2D among TB contacts is the low access to
healthcare in populations at risk for TB, who generally belong to the
lower socioeconomic strata [1]. This provides further support for the
contribution of TB clinics as hubs for new T2D diagnosis.
Our study across two continents also revealed metabolic diﬀerences
in the TB contacts with T2D. South Africans had a higher proportion of
high HbA1c in the presence of normal fasting blood glucose (Fig. 2).
Our study is not the ﬁrst to report disparities in HbA1c across ethnicities [15,26]. It has been hypothesized that higher HbA1c in Africans
may result from slower erythrocyte turnover or metabolism [26,27].
Another possibility is that elevated HbA1c in the South African cohort is
due to post-prandial glucose spikes despite normal fasting glucose. This
is known to vary between ethnicities [28]. To evaluate an overestimation of T2D among the South African contacts, we estimated the
proportion of T2D if we would have used an HbA1C cutoﬀ point of
6.9% as suggested previously [29] (e.g self-report of T2D, glucose ≥ 126 and/or HbA1C ≥ 6.9%). However, we found that the T2D
prevalence would be 42.1% with this variation, which is similar to the
43.2% calculated in our study.
Insulin resistance was associated with age and sex at both study
sites. However, two ﬁndings lead us to hypothesize that insulin resistance is largely driven by the higher levels of obesity and triglycerides in Texas-Mexico, and possibly inﬂuenced by host genetics in the
leaner population from South Africa. First, insulin resistance was associated with high BMI and triglycerides at both study sites, as would
be expected for T2D being driven by obesity [30]. However, in South
Africa, insulin resistance was also (unexpectedly) higher among individuals with normal triglycerides regardless of BMI, suggesting a
genetic component. Second, another unique feature of the South
African contacts was the higher insulin resistance among females, regardless of their BMI, triglycerides or age.
Lipid proﬁles also diﬀered by ethnicity with elevated triglycerides
more prevalent in Hispanics, and cholesterols in South African
Coloureds (Table 2; Fig. 4). While higher triglycerides are generally
related to obesity, higher cholesterol levels are likely attributed to host
genetics [31]. We speculate that high cholesterol may increase TB risk
beyond the baseline already conferred by T2D. Support for this is based
on reports that host cholesterol favors M. tuberculosis survival and
growth, increases TB susceptibility in a mouse model, and a lower risk

5. Conclusions
Our ﬁndings have two major implications. First, the high frequency
of new T2D patients among adult TB contacts warrants further investigation into the expansion of routine TB contacts investigations to
include T2D screening. These are likely to increase signiﬁcantly the
early diagnosis of T2D in economically disadvantaged populations at
risk for serious T2D complications and TB development. Second, elucidation of the risk conferred by T2D towards TB development or TB
treatment outcomes should be done in the context of other host sociodemographic and metabolic characteristics that may further boost or
restrain M. tuberculosis survival. We posit that the combination of these
variations confers diﬀerences in the “hierarchy” of TB risk and treatment outcomes, and future studies aimed at predicting TB risk among
the millions of T2D patients worldwide should analyze these host
variables.
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